Come up with a name for your new list and we'll add to it:
Phrixus Pharmaceuticals raised a round of funding on , . Investors include
Michigan Pre-Seed Capital Fund.
Phrixus Pharmaceuticals is developing Carmeseal (poloxamer 188 or P188) for Duchenne muscular dystrophy and acute decompensated heart failure. Carmeseal has been shown to improve the efficiency of dam…